The extensive propagation of Industrial Internet of things (IIoT) technologies has encouraged the intruders to initiate a variety of attacks that need to be identified to maintain the security of end-user data and the safety of services offered by service providers. Deep learning (DL), especially recurrent approaches, has been applied successfully to the analysis of IIoT forensics but their key challenge of recurrent DL models is that they struggle with long traffic sequences and can't be parallelized. Multi-head Attention (MHA) tried to address this shortfall but fails to capture the local representation of IIoT traffic sequences. In this paper, we propose a forensics-based DL model (called Deep-IFS) to identify intrusions in IIoT traffic. The model learns local representations using local gated recurrent unit (LocalGRU), and introduces an MHA layer to capture and learn global representation (i.e., long-range dependencies). A residual connection between layers is designed to prevent information loss. Another challenge facing the current IIoT forensics frameworks is their limited scalability, limiting performance in handling Big IIoT traffic data produced by IIoT devices. This challenge is addressed by deploying and training the proposed Deep-IFS in a fog computing environment. The intrusion identification becomes scalable by distributing the computation and the IIoT traffic data across worker fog nodes for training the model. The master fog node is responsible for sharing training parameters and aggregating worker nodes output. The aggregated classification output is subsequently passed to the cloud platform for mitigating attacks. Empirical results on the Bot-IIoT dataset demonstrate that the developed distributed Deep-IFS can effectively handle Big IIoT traffic data compared with the present centralized DL-based forensics techniques. Further, the results validate the robustness of the proposed Deep-IFS across various evaluation measures.
The rapid spread of novel coronavirus pneumonia (COVID-19) has led to a dramatically increased mortality rate worldwide. Despite many efforts, the rapid development of an effective vaccine for this novel virus will take considerable time and relies on the identification of drug-target (DT) interactions utilizing commercially available medication to identify potential inhibitors. Motivated by this, we propose a new framework, called DeepH-DTA, for predicting DT binding affinities for heterogeneous drugs. We propose a heterogeneous graph attention (HGAT) model to learn topological information of compound molecules and bidirectional ConvLSTM layers for modeling spatio-sequential information in simplified molecular-input line-entry system (SMILES) sequences of drug data. For protein sequences, we propose a squeezed-excited dense convolutional network for learning hidden representations within amino acid sequences; while utilizing advanced embedding techniques for encoding both kinds of input sequences. The performance of DeepH-DTA is evaluated through extensive experiments against cutting-edge approaches utilising two public datasets (Davis, and KIBA) which comprise eclectic samples of the kinase protein family and the pertinent inhibitors. DeepH-DTA attains the highest Concordance Index (CI) of 0.924 and 0.927 and also achieved a mean square error (MSE) of 0.195 and 0.111 on the Davis and KIBA datasets respectively. Moreover, a study using FDA-approved drugs from the Drug Bank database is performed using DeepH-DTA to predict the affinity scores of drugs against SARS-CoV-2 amino acid sequences, and the results show that that the model can predict some of the SARS-Cov-2 inhibitors that have been recently approved in many clinical studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.